Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.
Read More
Supporting companies across the healthcare ecosystem with flexible funding models…
Read More
Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.
Read More View Portfolio Companies
Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.
Read More View Research Collaborations
As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.
Read More
The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.
Read More Meet the Foundation Team
Cure is a 12-story innovation campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.
Read More Join the Cure Email ListCure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.
Events at the Cure
Published Jan. 4, 2023
By Kelly Bilodeau
Early-stage drug development typically comes with a heaping side of financial risk. As a result, promising academic research discoveries can languish in the uncertain R&D stages because there is no commercial funding to prove their market potential. Increasingly, nonprofits are stepping in to fill this gap, backing new ideas and bringing them to a point where pharma companies are willing to invest and carry them past the regulatory finish line.
